Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by SABBOBCATon Feb 27, 2020 12:28am
94 Views
Post# 30738891

RE:Hmmmm

RE:HmmmmI am glad we are on the same page in terms of the lack of board ownership. Have you, or do you plan to, bring this up with them? The fact that we are at these lows and the new board members aren't even close to hitting the Share Holding targets is ludicrous
SPCEO1 wrote: Officers and board members have seen sizable option grants from the past expire worthless this week. So, they are feeling at least some of the pain we are feeling as a result of the stock price’s fall.
 
Total compensation for all the officers fell in 2019 versus 2018, mostly due to significantly  reduced option grants. But the cash portion of their compensation actually increased, which seems ill-advised from my perspective given the stock’s very poor performance in 2019.
 
Overall, proxy circular left me somewhat irritated. While total compensation fell and older option grants expired worthless, cash compensation increased and some board members have little or no shareholdings. This is out of whack with the performance of the stock in 2019. Now, it is demonstrably true that the company is significantly better off now than at the beginning of 2019, but if management is not able to translate that improvement into a better stock price, there should be a bigger penalty than just reduced option grants. And certain new board members need to buy some shares in the company to exhibit a proper support for the company and to get in line with company policy as well.



Bullboard Posts